FDA clears Audentes’ IND application for AT342 to treat Crigler-Najjar syndrome
The IND is now active and Audentes plans to initiate VALENS, the multicenter, multinational, open-label, ascending dose phase 1 / 2 clinical study of AT342. Preliminary data from
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.